Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Transfusion and Agglutination

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...

Blood Transfusion

Blood Transfusion

Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...

Blood Pressure Imbalances and Circulatory Shock

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...

Esophageal Varices-II: Clinical Features and Management

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

VAV2 drives glycolytic reprogramming in esophageal squamous cell carcinoma via EIF3F-mediated MTA1 deubiquitination.

Cancer & metabolism·2026

Same author

Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study.

Frontiers in immunology·2026

Same author

The effect of enhanced external counterpulsation on sleep quality and quality of life in patients with chronic insomnia: study protocol for a randomized controlled trial.

BMC psychiatry·2026

Same author

An open multi-center MEG-EEG dataset for studying conscious visual perception.

Scientific data·2026

Same author

Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China.

Future oncology (London, England)·2026

Same author

Efficacy analysis of transurethral <i>en bloc</i> resection for bladder tumors ≥3 cm.

Translational andrology and urology·2026

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Generation of Hook Ischemia-Reperfusion Model using a Three-Day Developing Chick Embryo

Generation of Hook Ischemia-Reperfusion Model using a Three-Day Developing Chick Embryo

Published on: February 19, 2022

ELABELA: A Potential Therapeutic Target for Ischemia-Reperfusion Injury.

Wan Li¹, Cuicui Meng¹, Shujun Yang¹

¹Department of Emergency, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen 518033, China.

|February 27, 2026

Summary

Ischemia-reperfusion injury (IRI) causes further organ damage after blood flow is restored. The peptide hormone ELABELA (ELA) shows protective effects against IRI, offering a potential therapeutic target.

Keywords:

ELABELA angiogenesis apoptosis fibrosis inflammatory response ischemia–reperfusion injury oxidative stress

More Related Videos

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

Related Experiment Videos

Last Updated: Jun 24, 2026

Generation of Hook Ischemia-Reperfusion Model using a Three-Day Developing Chick Embryo

Generation of Hook Ischemia-Reperfusion Model using a Three-Day Developing Chick Embryo

Published on: February 19, 2022

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

Area of Science:

Biomedical science
Pathophysiology
Endocrinology

Background:

Ischemia-reperfusion injury (IRI) is a significant clinical challenge, causing secondary damage to tissues and organs upon reperfusion.
ELABELA (ELA), an endogenous peptide hormone, acts as a ligand for the APJ receptor and is involved in various physiological processes.

Purpose of the Study:

To review and synthesize current research on the protective role of ELABELA (ELA) in mitigating ischemia-reperfusion injury (IRI).

Main Methods:

Literature review of studies investigating ELABELA (ELA) and its effects on IRI.
Synthesis of findings across multiple organ systems.

Main Results:

Growing evidence highlights the cytoprotective properties of ELABELA (ELA) against IRI.
ELA demonstrates potential to mitigate IRI-induced damage in various organs.

Conclusions:

ELABELA (ELA) emerges as a promising endogenous factor for protecting against ischemia-reperfusion injury.
Further research into ELA-based therapies could offer new strategies for managing IRI.